What does 97.1% purity on a C8 column actually tell me about a tirzepatide vial?

Numbers first: 97.1% · a C8 column · tirzepatide.

This is presented as though it settles something, and I am not convinced it does.

I have two documents that appear to disagree, which is what prompted this.

Which parts of this are informative and which are decoration?

It tells you 97.1 per cent of the integrated area came off a C8 column where tirzepatide comes off, and the remaining 2.9 per cent did not. That is an area statement at one wavelength, not a mass statement about the vial: 2.9 per cent of area is only 2.9 per cent of mass if every impurity absorbs exactly as strongly as the parent, which none of them do. It also says nothing about how many milligrams are in the glass — water, counter-ion and a short fill are all invisible to it. What a C8 column does add is a constraint on what could be hiding: a column that retains by hydrophobicity separates deletion sequences well and separates isomers of identical hydrophobicity not at all.

The method is the measurement in reverse-phase chromatography, more so than in almost any other analytical domain, and two methods that look identical can easily produce different results.

The 214 nanometre wavelength is chosen because it corresponds to the amide backbone absorption, making response roughly proportional to the number of peptide bonds.

Reconciling gross mass to label claim

System suitability checks on replicate injections of a known standard establish whether the method was in control — if the peak area varies by more than two per cent between replicates, something is wrong.

Peptide separation by reverse-phase high-performance liquid chromatography is described in the general chapters of the United States Pharmacopeia, European Pharmacopeia and Japanese Pharmacopeia, and the methods converge on essentially the same principles.

The caveat is that HPLC is a purity technique and says almost nothing about whether the main peak is actually your target compound — that is why identity confirmation from mass spectrometry or peptide mapping matters.

The practical summary: specify the method, run the same method on every sample you compare, and use orthogonal techniques to confirm the result.

Reverse-phase HPLC is the workhorse for peptide purity work, but it is almost universally run under conditions that are not optimal for a peptide of this chain length.

Wider-pore phases — 300 Angstrom rather than 100 Angstrom — have faster mass transfer and narrower peaks for peptides above three kilodaltons, which is almost every peptide you will see.

Worth being precise here: acetonitrile is the organic modifier of choice because it has a good UV cutoff, a reasonable viscosity and a refractive index that minimises baseline noise.

The resolving power of a separation is quantified by the resolution parameter R, defined from the heights and widths of adjacent peaks, and pharmacopoeial methods typically demand R greater than 1.5 for a method to be considered validated.

If two labs give different numbers, the method difference is the first hypothesis, not lab quality.

edited 28 May 2026 by nine_point_nine — added a caveat about sampling

The underlying point is that high-performance liquid chromatography is a separation technique, not an identification technique, and it answers the question "how much of the detected signal is a single species" not "which species is it."

Trifluoroacetic acid at 0.1 per cent is the standard ion-pairing agent because it suppresses tailing by neutralising the basic residues, but it also suppresses mass spectrometry signal.

The relevant detail is that sample preparation is almost always under-appreciated — a reconstituted peptide in strong solvent will distort its own peak on the gradient.

The limitation is that co-elution is invisible — if two species happen to have the same retention time, they will report as a single peak at their combined area.

Ask for the chromatogram and the system suitability data, not just the number.

Gradient design is usually described as though it is a minor technical detail rather than the primary determinant of what the method measures.

Detector linearity is why a heavily loaded peak can give false purity by compressing the main peak height while leaving impurity shoulders unchanged.

Peptide impurities from solid-phase synthesis include deletion sequences, truncations from premature cleavage, racemised residues from epimerisation and oxidised variants, each of which may have different chromatographic behaviour.

If you only pay for one test, pay for quantified content. Purity is the number everyone quotes and content is the number that changes what you do.

Start by understanding what the detector is measuring and what that means about how the molecule needs to be prepared and handled before injection.

Reverse-phase stationary phases use C18 or C8 chains bonded to silica, and the pore size of the silica matters more for a peptide of this chain length than the ligand length does.

Worth noting that the achievable resolution depends on the chemistry of the molecule — some peptide sequences separate easily while others are notoriously difficult regardless of method.

In practice: ask for the chromatogram, check the method section, check the lot number against the vial, and set your accept threshold before you see the result rather than after.